Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. News
  7. Summary
    REC   IT0003828271

RECORDATI

(REC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RECORDATI: 2022 CORPORATE EVENTS' CALENDAR

10/11/2021 | 06:42am EST

NEWS RELEASE

RECORDATI: 2022 CORPORATE EVENTS' CALENDAR

Milan, 11th October 2022 - Recordati S.p.A. hereby communicates the calendar of corporate events for 2022:

24 th February

Board of Directors' meeting to approve the 2021 preliminary consolidated results.

17th March

Board of Directors' meeting to approve the 2021 consolidated financial statements

and the draft of Recordati S.p.A.'s 2021 financial statements as well as the 2021

consolidated non-financial statement.

29th April

Annual Shareholders' Meeting to approve Recordati S.p.A.'s 2021 financial

statements.

10th May

Board of Directors' meeting to approve the 2022 first quarter results.

28th July

Board of Directors' meeting to approve the 2022 half-yearly report.

8th November

Board of Directors' meeting to approve the 2022 first nine months' results.

Recordati S.p.A. announces that the payment of the balance of the 2021 financial year dividend is planned for May 2022, while payment of the interim dividend for the 2022 financial year is planned for November 2022.

Information on payment date, ex-dividend date and record date will be provided after the disclosure of the 2022 trading Calendar of Borsa Italiana.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.

For further information:

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1

Share Capital € 26.140.644,50 fully paid-up

20148 Milano, Italy

Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Ph. (39) 02 487871

Tax Code/VAT No. 00748210150

Fax (39) 02 40073747

Milano R.E.A. No. 401832

www.recordati.com

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l

Recordati website: www.recordati.com

Investor Relations

Media Relations

Federica De Medici

Brunswick - Barbara Scalchi / Andrea Mormandi

(39) 02 48787146

(39) 02 9288 6200

e-mail: investorelations@recordati.it

e-mail: recordati@brunswickgroup.com

2

Disclaimer

Recordati S.p.A. published this content on 11 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 October 2021 10:41:03 UTC.


ę Publicnow 2021
All news about RECORDATI
01/25ITA chairman welcomes MSC, Lufthansa offer - Handelsblatt
RE
01/24Shipping group MSC, Lufthansa offer to buy Alitalia successor
RE
01/20ITA says airport incentives to low-cost airlines risk causing a "blood bath"
RE
01/12ITA Airways seeks an ally to put 'money on the table'
RE
2021Eton Pharmaceuticals, ANI Pharmaceuticals Launch Carglumic Acid Tablets for Hyperammone..
MT
2021RECORDATI : Kim stratton co-opted to the board of directors as a non-executive and non-ind..
PU
2021RECORDATI : Presentazione EUSA Pharma Acquisition
PU
2021RECORDATI : EUSA Pharma Acquisition
PU
2021Recordati To Acquire EUSA Pharma In $847 Million Deal
MT
2021Recordati to buy EUSA Pharma for $847 million to boost rare disease offering
RE
More news
Analyst Recommendations on RECORDATI
More recommendations
Financials
Sales 2021 1 579 M 1 782 M 1 782 M
Net income 2021 408 M 461 M 461 M
Net Debt 2021 876 M 988 M 988 M
P/E ratio 2021 25,9x
Yield 2021 2,24%
Capitalization 10 306 M 11 625 M 11 631 M
EV / Sales 2021 7,08x
EV / Sales 2022 6,58x
Nbr of Employees 4 446
Free-Float -
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 49,95 €
Average target price 50,54 €
Spread / Average Target 1,17%
EPS Revisions
Managers and Directors
Robert Koremans Chief Executive Officer
Luigi Felice la Corte Group Chief Financial Officer
Andrea Recordati Chairman
Raffaele Sabia Senior VP-Pharmaceutical Research & Development
Giovanni Minora Head-Group Audit & Compliance
Sector and Competitors
1st jan.Capi. (M$)
RECORDATI-11.59%11 625
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093